Skip to main content

Vertex Pharmaceuticals cash flow statement

  • VRTX · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$538.60−0.74%Close 13 Nov 2026

In fiscal 2025 (the year to 31 Dec 2025), Vertex Pharmaceuticals generated $3.63B of operating cash flow and $3.19B of free cash flow, after $437.6M of capital expenditure.

From Vertex Pharmaceuticals's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Vertex Pharmaceuticals cash flow statement, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Net income−$459.9M−$642.2M−$754.6M$29.57M−$107.0M−$445.0M−$738.6M−$556.3M−$112.1M$263.5M$2.10B$1.18B$2.71B$2.34B$3.32B$3.62B−$535.6M$3.95B$3.98B
Depreciation & amortization$32.20M$30.11M$30.46M$35.04M$38.19M$48.37M$63.26M$62.34M$61.40M$61.40M$72.42M$106.9M$109.5M$125.6M$148.3M$181.3M$207.2M$209.8M$237.3M
Stock-based compensation$57.98M$86.72M$91.12M$118.2M$114.3M$127.3M$177.5M$231.0M$240.6M$293.2M$325.0M$360.5M$429.5M$441.4M$491.3M$581.2M$698.5M$685.9M$668.6M
Operating cash flow−$226.5M−$427.6M−$635.4M$143.7M$267.8M−$60.67M−$573.1M−$365.4M$236.1M$844.9M$1.27B$1.57B$3.25B$2.64B$4.13B$3.54B−$492.6M$3.63B$3.69B
Operating cash flow margin−129%−420%−443%10.2%17.5%−5.0%−98.7%−35.4%13.9%34.0%41.7%37.7%52.4%34.9%46.2%35.8%−4.5%30.3%28.5%
Capital expenditures$32.18M$23.50M$38.05M$34.59M$71.14M$51.39M$51.20M$45.30M$56.56M$99.42M$95.45M$75.40M$259.8M$235.0M$204.7M$200.4M$297.7M$437.6M$492.3M
Acquisitions—$87.42M———————$0.00$0.00$1.15B$0.00$0.00$295.9M$0.00$0.00——
Free cash flow−$258.7M−$451.1M−$673.5M$109.1M$196.7M−$112.1M−$624.3M−$410.7M$179.5M$745.5M$1.17B$1.49B$2.99B$2.41B$3.93B$3.34B−$790.3M$3.19B$3.20B
Free cash flow margin−147%−443%−470%7.7%12.9%−9.2%−108%−39.8%10.5%30.0%38.5%35.9%48.2%31.8%44.0%33.8%−7.2%26.6%24.7%
Free cash flow per share−$1.84−$2.60−$3.36$0.52$0.91−$0.50−$2.65−$1.70$0.73$2.94$4.53$5.73$11.37$9.27$15.15$12.81−$3.06$12.38$12.52
Gross share repurchases————————$0.00$0.00$350.0M$186.0M$539.1M$1.43B$0.00$427.6M$1.18B$2.02B$1.06B
Stock issuance proceeds$330.1M$801.4M$33.43M$124.9M$191.7M$265.9M$274.6M$165.6M$48.50M$323.3M$263.4M$317.8M$228.2M$64.20M$144.6M$80.80M$50.00M$55.60M—
Net share repurchases−$330.1M−$801.4M−$33.43M−$124.9M−$191.7M−$265.9M−$274.6M−$165.6M−$48.50M−$323.3M$86.64M−$131.8M$310.9M$1.36B−$144.6M$346.8M$1.13B$1.96B$1.06B
Cash interest paid$6.68M$10.25M$761.0K$13.51M$13.40M$13.46M$68.96M$85.61M$83.66M$68.70M$66.46M$55.60M$54.50M$56.30M$52.30M$43.10M$30.50M$12.40M$12.20M
Free cash flow after SBC−$316.6M−$537.8M−$764.6M−$9.09M$82.42M−$239.4M−$801.9M−$641.8M−$61.08M$452.3M$849.8M$1.13B$2.56B$1.97B$3.43B$2.76B−$1.49B$2.51B$2.53B

Quarterly

Vertex Pharmaceuticals cash flow statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Net income$968.8M$1.10B−$3.59B$1.05B$913.0M$646.3M$1.03B$1.08B$1.19B$1.03B$1.10B$653.6M
Depreciation & amortization$59.00M$53.50M$54.00M$53.20M$46.50M$48.40M$51.70M$54.00M$55.70M$55.90M$56.50M$69.20M
Stock-based compensation$208.6M$191.9M$154.2M$184.6M$167.8M$166.1M$167.3M$194.9M$157.6M$166.4M$170.2M$174.4M
Operating cash flow$234.6M$1.31B−$3.75B$1.37B$584.6M$818.9M$1.07B$1.24B$498.0M$1.43B$1.13B$643.1M
Operating cash flow margin9.3%48.6%−142%49.4%20.1%29.6%36.2%40.4%15.6%47.8%33.8%18.7%
Capital expenditures$58.10M$68.40M$69.00M$67.70M$92.60M$40.70M$145.7M$101.8M$149.4M$133.4M$112.2M$97.30M
Acquisitions$0.00———————————
Free cash flow$176.5M$1.24B−$3.82B$1.30B$492.0M$778.2M$927.4M$1.14B$348.6M$1.29B$1.01B$545.8M
Free cash flow margin7.0%46.0%−144%47.0%16.9%28.1%31.3%37.0%10.9%43.3%30.4%15.9%
Free cash flow per share$0.68$4.74−$14.81$4.99$1.91$3.00$3.58$4.42$1.36$5.05$3.97$2.14
Gross share repurchases$149.5M$131.2M$320.3M$307.7M$417.9M$426.1M$391.8M$1.07B$128.4M$336.9M$469.5M$126.7M
Stock issuance proceeds—————————$27.00M$47.70M$22.90M
Net share repurchases$149.5M$131.2M$320.3M$307.7M$417.9M$426.1M$391.8M$1.07B$128.4M$309.9M$421.8M$103.8M
Cash interest paid$10.50M$10.00M$9.70M$8.10M$2.70M$2.70M$3.50M$3.20M$3.00M$3.20M$3.10M$2.90M
Free cash flow after SBC−$32.10M$1.05B−$3.98B$1.12B$324.2M$612.1M$760.1M$944.7M$191.0M$1.13B$843.0M$371.4M

The main figures as JSON and plain text. See data and methodology.

VRTX in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.